Press coverage about Bio-Rad Laboratories (NYSE:BIO) has trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Bio-Rad Laboratories earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave media stories about the medical research company an impact score of 45.9367611723964 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news articles that may have impacted Accern Sentiment Analysis’s scoring:
- Wells Fargo Starts Coverage on Bio-Rad Laboratories, Inc. Clas (BIO) By Announcing An Initial Rating Of “Outperform” (highlightpress.com)
- Jefferies Group LLC Reaffirms “Buy” Rating for Bio-Rad Laboratories, Inc. (BIO) (americanbankingnews.com)
- Europe In-Vitro Diagnostics Market by Products (Instruments, Reagents and Kits, & Software) (emailwire.com)
- Global Polymerase Chain Reaction Market Is Expected to Reach a CAGR of 9.91% During the Forecast Period 2017 – 2023; Finds New Report (sbwire.com)
- In Vitro Diagnostics Quality Control Market by Application, Source, Type – Global Forecast to 2022 (bizjournals.com)
Several research firms have recently weighed in on BIO. BidaskClub upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Thursday, June 22nd. Zacks Investment Research upgraded shares of Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a research report on Monday, March 27th. Wells Fargo & Company initiated coverage on shares of Bio-Rad Laboratories in a research report on Thursday, July 13th. They set an “outperform” rating and a $250.00 price objective for the company. Jefferies Group LLC reiterated a “buy” rating and issued a $275.00 target price on shares of Bio-Rad Laboratories in a report on Friday. Finally, Deutsche Bank AG upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating and decreased their target price for the stock from $220.00 to $195.00 in a report on Wednesday, June 28th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $228.80.
Shares of Bio-Rad Laboratories (NYSE BIO) opened at 232.01 on Tuesday. The stock has a 50 day moving average of $222.92 and a 200-day moving average of $202.79. Bio-Rad Laboratories has a 52-week low of $142.06 and a 52-week high of $233.51. The stock has a market capitalization of $6.87 billion, a price-to-earnings ratio of 246.30 and a beta of 0.91.
Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Thursday, May 4th. The medical research company reported $0.41 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.27 by $0.14. Bio-Rad Laboratories had a return on equity of 3.23% and a net margin of 1.35%. The company had revenue of $500.05 million during the quarter, compared to analyst estimates of $477.76 million. During the same period in the previous year, the company earned $0.42 EPS. The company’s revenue for the quarter was up 6.1% compared to the same quarter last year. On average, equities research analysts predict that Bio-Rad Laboratories will post $2.94 EPS for the current fiscal year.
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.
Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.